Itraconazole in human medicine and veterinary practice

IF 2.2 4区医学 Q3 MYCOLOGY Journal de mycologie medicale Pub Date : 2024-03-11 DOI:10.1016/j.mycmed.2024.101473

Yamara V Sousa , Marie G Santiago , Bianca M de Souza , Kelly M Keller , Camila S F Oliveira , Leonel Mendoza , Raquel V R Vilela , Gisele A C Goulart

{"title":"Itraconazole in human medicine and veterinary practice","authors":"Yamara V Sousa , Marie G Santiago , Bianca M de Souza , Kelly M Keller , Camila S F Oliveira , Leonel Mendoza , Raquel V R Vilela , Gisele A C Goulart","doi":"10.1016/j.mycmed.2024.101473","DOIUrl":null,"url":null,"abstract":"<div><p>Diagnosis and management of fungal infections are challenging in both animals and humans, especially in immunologically weakened hosts. Due to its broad spectrum and safety profile when compared to other antifungals, itraconazole (ITZ) has been widely used in the treatment and prophylaxis of fungal infections, both in human and veterinary medicine. The dose and duration of management depend on factors such as the type of fungal pathogen, the site of infection, sensitivity to ITZ, chronic stages of the disease, the health status of the hosts, pharmacological interactions with other medications and the therapeutic protocol used. In veterinary practice, ITZ doses generally vary between 3 mg/kg and 50 mg/kg, once or twice a day. In humans, doses usually vary between 100 and 400 mg/day. As human and veterinary fungal infections are increasingly associated, and ITZ is one of the main medications used, this review addresses relevant aspects related to the use of this drug in both clinics, including case reports and different clinical aspects available in the literature.</p></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal de mycologie medicale","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1156523324000143","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MYCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Diagnosis and management of fungal infections are challenging in both animals and humans, especially in immunologically weakened hosts. Due to its broad spectrum and safety profile when compared to other antifungals, itraconazole (ITZ) has been widely used in the treatment and prophylaxis of fungal infections, both in human and veterinary medicine. The dose and duration of management depend on factors such as the type of fungal pathogen, the site of infection, sensitivity to ITZ, chronic stages of the disease, the health status of the hosts, pharmacological interactions with other medications and the therapeutic protocol used. In veterinary practice, ITZ doses generally vary between 3 mg/kg and 50 mg/kg, once or twice a day. In humans, doses usually vary between 100 and 400 mg/day. As human and veterinary fungal infections are increasingly associated, and ITZ is one of the main medications used, this review addresses relevant aspects related to the use of this drug in both clinics, including case reports and different clinical aspects available in the literature.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

伊曲康唑在人类医学和兽医实践中的应用

真菌感染的诊断和治疗对动物和人类都具有挑战性，尤其是免疫力低下的宿主。与其他抗真菌药物相比，伊曲康唑（ITZ）具有广谱性和安全性，因此已被广泛用于人类和兽医真菌感染的治疗和预防。治疗的剂量和持续时间取决于多种因素，如真菌病原体的类型、感染部位、对 ITZ 的敏感性、疾病的慢性阶段、宿主的健康状况、与其他药物的药理作用以及所使用的治疗方案。在兽医实践中，ITZ 的剂量一般在 3 毫克/千克到 50 毫克/千克之间，每天 1 次或 2 次。对于人类，剂量通常在 100-400 毫克/天之间。由于人类和兽医真菌感染的关联性越来越强，而 ITZ 是主要的药物之一，因此本综述将讨论在这两种临床中使用该药物的相关方面，包括病例报告和文献中的不同临床方面。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal de mycologie medicale 医学-真菌学

CiteScore

5.10

自引率

2.80%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal de Mycologie Medicale / Journal of Medical Mycology (JMM) publishes in English works dealing with human and animal mycology. The subjects treated are focused in particular on clinical, diagnostic, epidemiological, immunological, medical, pathological, preventive or therapeutic aspects of mycoses. Also covered are basic aspects linked primarily with morphology (electronic and photonic microscopy), physiology, biochemistry, cellular and molecular biology, immunochemistry, genetics, taxonomy or phylogeny of pathogenic or opportunistic fungi and actinomycetes in humans or animals. Studies of natural products showing inhibitory activity against pathogenic fungi cannot be considered without chemical characterization and identification of the compounds responsible for the inhibitory activity. JMM publishes (guest) editorials, original articles, reviews (and minireviews), case reports, technical notes, letters to the editor and information. Only clinical cases with real originality (new species, new clinical present action, new geographical localization, etc.), and fully documented (identification methods, results, etc.), will be considered. Under no circumstances does the journal guarantee publication before the editorial board makes its final decision. The journal is indexed in the main international databases and is accessible worldwide through the ScienceDirect and ClinicalKey platforms.